On November 3, 2023 Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, reported data from two poster presentations being presented tomorrow, November 4, 2023, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting in San Diego, CA (Press release, Fulgent Genetics, NOV 3, 2023, View Source [SID1234636929]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These data support our mission to build a holistic platform to provide comprehensive solutions and services across the cancer care continuum, including early detection, diagnostics, and monitoring, as well as drug discovery and development," said Ming Hsieh, Chairman and CEO of Fulgent Genetics and co-founder of Fulgent Therapeutics. "We see strong momentum in our precision diagnostics business as a driver of core revenue, and we are encouraged by the steady progress of our therapeutic development for FID-007 in oncology indications."

The poster titled, "Critical clinical evaluation of plasma to tumor tissue concordance by cancer type using Illumina’s cell-free ctTSO500 commercial liquid biopsy assay," explores the critical role of comparing ctDNA variants detected in plasma with those found in tissue, shedding light on the practical implementation of liquid biopsy technology. The research presents a meticulous analysis of plasma-to-tissue concordance across various cancer types, offering valuable insights into the considerations for validation, using Illumina’s cutting-edge ctTSO500 commercial liquid biopsy assay. The clinical research findings, based on a comprehensive examination of 124 cases across different cancers, reveal significant concordance variations, often linked to the cancer stage and the timing of biopsy and blood sample collection. In uterine cancers, the researchers detected 65.9% of the SNV/indel variants in plasma that were also in FFPE, 47% in colon cancer, 67% in gastric cancer, 56% in bladder cancer, 51% in larynx cancer, and 41% in prostate. The study calls for the involvement of certified labs, highlighting the need for stringent quality management and regulatory alignment. The research ultimately underscores the reproducibility, sensitivity, and practical importance of Illumina’s ctTSO500 liquid biopsy, particularly for patients who either cannot or prefer not to undergo traditional solid biopsies for cancer screening.

The poster titled, "FID-007: Nanoencapsulated Paclitaxel Derived from a Novel Nano-Drug Delivery Platform," highlights progress for Fulgent Pharma’s lead therapeutic oncology candidate, FID-007, in various cancers. Similar to data presented at the ASCO (Free ASCO Whitepaper) Annual Meeting in June, of 40 evaluable patients with weekly dose levels from 15 mg/m2 to 160 mg/m2, 7 (18%) had a partial response (PR) by RECIST 1.1 (pancreatic, biliary tract, and HNSCC) and 14 (35%) had stable disease. Three out of 4 HNSCC patients with PR had previously been treated with taxane. The duration of follow-up (months), median (range) is 12.0 (0.4 – 38.9). No high-grade neuropathy has been noted to date. Preliminary clinical data suggests FID-007 may have anti-tumor activity in heavily pre-treated patients across various tumor types. Based on the lack of adverse events, pharmacokinetics, and early indications of treatment effect, 125 mg/m2 has been chosen as the recommended Phase 2 dose. In addition, subgroup analysis based on 7 patients for Head and Neck cancer and 4 patients for Ampullary/Pancreatic cancer showed 57% and 50% objective response rate, respectively.

The posters will be available on the Investor Relations section of the company’s website at View Source

About FID-007

FID-007 consists of paclitaxel encapsulated in a polyethyloxazoline (PEOX) polymer excipient designed to enhance PK, biodistribution, and tolerability. In addition to allowing the drug to remain in solution until it can enter a cancer cell, the PEOX nanoparticle is designed to preferentially deliver paclitaxel to the tumor through the leaky hyperpermeable vasculature.